This Equifax Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Benzinga·08/21 14:29
Share
Listen to the news
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Baird analyst Andrew Wittmann upgraded Parsons Corp(NYSE:PSN) from Neutral to Outperform and raised the price target from $48 to $57. Parsons closed at $46.06 on Thursday. See how other analysts view this stock.
Keybanc analyst Matthew Gillmor upgraded InnovAge Holding Corp(NASDAQ:INNV) from Sector Weight to Overweight and announced a $13 price target. InnovAge shares closed at $10.72 on Thursday. See how other analysts view this stock.
Rothschild & Co analyst Simon Clinch upgraded Equifax Inc(NYSE:EFX) from Neutral to Buy and raised the price target from $214 to $235. Equifax closed at $192.41 on Thursday. See how other analysts view this stock.
JP Morgan analyst Tomohiko Sano upgraded TIC Solutions Inc (NYSE:TIC) from Underweight to Neutral and raised the price target from $9 to $11. TIC Solutions shares closed at $9.02 on Thursday. See how other analysts view this stock.
Morgan Stanley analyst Carlos De Alba upgraded Ternium S.A. (NYSE:TX) from Equal-Weight to Overweight and raised the price target from $55 to $65. Ternium closed at $54.21 on Thursday. See how other analysts view this stock.
Considering buying EFX stock? Here’s what analysts think:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.